(May 30, 2024, 1:53 PM EDT) -- NEW ORLEANS — Companies embroiled in a Louisiana take-home asbestos lung cancer suit moved to compel production of a blood sample for whole genome sequencing, pointing out that limited testing on a sample of the plaintiff’s tumor and her family history all suggest she suffers from a germline mutation that the requested testing could confirm....